View Older Stories View More Recent Stories

Oct 24, 2023 08:00AM Cellectar Biosciences to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 2, 2023
Oct 17, 2023 08:00AM Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia
Oct 2, 2023 06:55AM Cellectar Biosciences (CLRB) Expands Global Intellectual Property Portfolio with Four Patent Grants
Oct 2, 2023 06:35AM Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants
Sep 18, 2023 08:41AM Cellectar Biosciences (CLRB) Receives European Medicines Agency Priority Medicines Designation for Iopofosine for Waldenstrom’s Macroglobulinemia
Sep 18, 2023 08:40AM Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia
Sep 11, 2023 06:30AM Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing
Sep 5, 2023 08:22AM Cellectar Biosciences (CLRB) Announces $103M Private Offering at $1.82/sh
Sep 5, 2023 08:21AM Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing
Aug 14, 2023 08:40AM Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update
Jun 28, 2023 08:30AM Cellectar Biosciences Highlights Promising Interim Data from Its Ongoing Study of Iopofosine I 131 in Multiple Myeloma in an Oral Presentation at the SNMMI Annual Meeting
Jun 12, 2023 08:30AM Cellectar Provides a Research and Development Program Summary
May 4, 2023 09:22AM UPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update
May 4, 2023 08:40AM Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update
Mar 27, 2023 04:05PM MaxCyte, Inc. (MXCT) Appoints Douglas Swirsky as CFO
Mar 27, 2023 04:05PM MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
Mar 27, 2023 04:05PM MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
Mar 9, 2023 08:40AM Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update
Mar 8, 2023 04:05PM Cellectar to Participate at Upcoming Banking Conferences
Feb 28, 2023 08:32AM Cellectar Biosciences (CLRB) Reports Complete Response in a Relapsed/Refractory CNS Lymphoma Patient
Feb 28, 2023 08:30AM Cellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma Patient
Feb 15, 2023 08:30AM Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical
Nov 30, 2022 08:30AM Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer
Nov 21, 2022 08:30AM Cellectar Biosciences Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference
Nov 16, 2022 08:30AM Cellectar Announces Resolution of Breach of Contract and Intellectual Property Dispute
Nov 3, 2022 08:30AM Cellectar Reports Financial Results for Third Quarter 2022 and Provides a Corporate Update
Sep 22, 2022 08:30AM Cellectar Biosciences (CLRB) Announces $2M Grant to Expand Phase 1 Study of Iopofosine I 131
Sep 22, 2022 08:30AM Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors
Sep 13, 2022 08:30AM Cellectar Biosciences (CLRB) Reports Publication of Data from Expansion Cohort of Phase II CLOVER-1 Study of I-131
Sep 13, 2022 08:30AM Cellectar Announces Publication of Data from Its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Nature’s Blood Cancer Journal
Aug 5, 2022 08:30AM Cellectar Reports Financial Results for Second Quarter 2022
Jul 21, 2022 04:16PM Cellectar Biosciences (CLRB) Announces 1:10 Reverse Stock Split
Jul 21, 2022 04:15PM Cellectar Announces Stock Consolidation
May 10, 2022 08:30AM Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update
Apr 26, 2022 08:07AM Cellectar Biosciences (CLRB) Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom’s Macroglobulinemia
Apr 26, 2022 08:00AM Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom’s Macroglobulinemia
Apr 12, 2022 08:30AM Cellectar Biosciences Announces Key Commercial Team Appointments  
Mar 21, 2022 08:30AM Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update
Mar 10, 2022 04:05PM Cellectar to Participate at Upcoming Banking Conferences
Feb 23, 2022 08:00AM Cellectar Biosciences Announces Executive Leadership Changes
Jan 4, 2022 08:30AM Cellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect Conference
Dec 13, 2021 08:32AM Cellectar Biosciences (CLRB) Reports Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131
Dec 13, 2021 08:30AM Cellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting and Exposition
Dec 8, 2021 08:30AM Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition
Nov 16, 2021 08:33AM Cellectar Biosciences (CLRB) Reports Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study
Nov 16, 2021 08:30AM Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors
Nov 15, 2021 11:01AM Kazia Therapeutics (KZIA) Appoints John Friend as Chief Medical Officer
Nov 15, 2021 11:00AM Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer
Nov 8, 2021 08:30AM Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update
Nov 2, 2021 08:33AM Cellectar Biosciences (CLRB) Appoints Laurence Reilly as Interim Chief Medical Officer
View More Recent Stories View Older Stories